4.6 Article

Case Report: Ensartinib for gastric epithelioid inflammatory myofibrosarcoma with STRN-ALK fusion

Related references

Note: Only part of the references are listed.
Article Oncology

First case report of ensartinib in a patient with metastatic ALK rearranged lung cancer with ALK I1171N mutation: a case report

Shuang Yang et al.

Summary: This article reports a female lung adenocarcinoma patient with acquired ALK resistance mutation (ALK 11171N) who showed significant symptom improvement after treatment with ensartinib for 20 days, with the side effect of mild rash. Follow-up images revealed no further brain metastases after 3 months. This treatment may offer a new therapeutic strategy for ALK TKIs resistant patients, particularly at position 1171 of ALK exon20.

WORLD JOURNAL OF SURGICAL ONCOLOGY (2023)

Article Oncology

Case report: Epithelioid inflammatory myofibroblastic sarcoma treated with an ALK TKI ensartinib

Mengmeng Li et al.

Summary: Epithelioid inflammatory myofibroblastic sarcoma (EIMS) is an aggressive variant of inflammatory myofibroblastic tumor (IMT) with poor prognosis. EIMS is characterized by epithelioid morphology, neutrophilic infiltrate, and specific fusion partners of anaplastic lymphoma kinase (ALK). ALK tyrosine kinase inhibitors (TKIs) are recommended as therapy for EIMS, although there is no standard treatment. This study presented a case of successful targeted therapy with ensartinib in a patient with recurrence and multiple metastases, showing sustained partial response and no recurrence for 4 months.

FRONTIERS IN ONCOLOGY (2023)

Review Biochemistry & Molecular Biology

Mutated KIT Tyrosine Kinase as a Novel Molecular Target in Acute Myeloid Leukemia

Seiichiro Katagiri et al.

Summary: This paper discusses the role of KIT mutations and the potential of precision medicine in acute myeloid leukemia (AML). New therapies targeting KIT mutations show promise as effective treatments for AML.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Review Oncology

Inflammatory Myofibroblastic Tumour: State of the Art

Louisre Gros et al.

Summary: Inflammatory myofibroblastic tumor (IMT) is an extremely rare subtype of sarcoma with specific oncogene-driven mechanisms. Early identification of gene rearrangement is important for accurate treatment in advanced stages. Surgery is the preferred treatment for localized tumors, while the treatment for advanced disease is still unclear. Targeted therapy, particularly with tyrosine kinase inhibitors, plays a significant role in the management of IMT.

CANCERS (2022)

Article Oncology

Case Report: Efficacy of ensartinib treatment in pulmonary inflammatory myofibroblastic tumor with a rare GCC2-ALK fusion

Wenguang He et al.

Summary: This study reports a rare case of IMT with GCC2-ALK fusion and demonstrates for the first time that ensartinib as a TKI has clinical benefits for IMT.

FRONTIERS IN ONCOLOGY (2022)

Article Oncology

STRN-ALK Fusion in Lung Adenocarcinoma with Brain Metastasis Responded Well to Ensartinib: A Case Report

Linlin Zhang et al.

Summary: This case report describes a lung adenocarcinoma patient with brain metastasis harboring STRN-ALK fusion, who showed a positive response to ensartinib treatment. It provides valuable information for therapeutic strategy selection in NSCLC patients with STRN-ALK fusion.

CURRENT ONCOLOGY (2022)

Review Biochemistry & Molecular Biology

A holistic view on c-Kit in cancer: Structure, signaling, pathophysiology and its inhibitors

Shelly Pathania et al.

Summary: Receptor tyrosine kinases, such as c-Kit, play crucial roles in cellular processes and their dysregulation can lead to diseases like cancer. Different mutant isoforms of c-Kit have been implicated in various cancers, making c-Kit inhibition a promising approach for cancer treatment. More research is needed to understand the structure, signaling pathways, and pharmacophores of c-Kit inhibitors for improved selectivity and efficacy in cancer therapy.

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2021)

Review Oncology

The Transcriptional Roles of ALK Fusion Proteins in Tumorigenesis

Stephen P. Ducray et al.

CANCERS (2019)

Article Otorhinolaryngology

A Rare Presentation of Inflammatory Myofibroblastic Tumor in the Nasolabial Fold

Hind K. Alshammari et al.

CASE REPORTS IN OTOLARYNGOLOGY (2019)

Article Endocrinology & Metabolism

ETV6-NTRK3 and STRN-ALK kinase fusions are recurrent events in papillary thyroid cancer of adult population

Andre Uchimura Bastos et al.

EUROPEAN JOURNAL OF ENDOCRINOLOGY (2018)

Article Pathology

Mouse Model of Poorly Differentiated Thyroid Carcinoma Driven by STRN-ALK Fusion

Alyaksandr Nikitski et al.

AMERICAN JOURNAL OF PATHOLOGY (2018)

Article Pathology

Two Cases of Renal Cell Carcinoma Harboring a Novel STRN-ALK Fusion Gene

Hironori Kusano et al.

AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2016)

Review Oncology

The next-generation ALK inhibitors

Georg Pall

CURRENT OPINION IN ONCOLOGY (2015)

Letter Medicine, General & Internal

Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer REPLY

Alice T. Shaw et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

Article Multidisciplinary Sciences

Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer

Lindsey M. Kelly et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)

Article Medicine, General & Internal

Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer

Alice T. Shaw et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

Review Pathology

Inflammatory myofibroblastic tumours: where are we now?

B. C. Gleason et al.

JOURNAL OF CLINICAL PATHOLOGY (2008)

Review Oncology

The anaplastic lymphoma kinase in the pathogenesis of cancer

Roberto Chiarle et al.

NATURE REVIEWS CANCER (2008)

Review Anatomy & Morphology

KIT (CD117): A review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation

M Miettinen et al.

APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2005)

Article Pathology

TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors

B Lawrence et al.

AMERICAN JOURNAL OF PATHOLOGY (2000)